Module
HIV Journal Options – Volume 5, Issue 2
Source: Journal Options
HIV Journal Options – Volume 5, Issue 2
Program Directors: Joseph J. Eron, Jr., MD, William G. Powderly, MD, Andrew R. Zolopa, MD
  
- Keith Henry, MD
- Paul Krogstad, MD
- Kristine Patterson, MD
|
  
- Amanda Peppercorn, MD
- Gerald Pierone, Jr. , MD
- Paul E. Sax, MD
|
 
- Timothy R. Sterling, MD
- Timothy Wilkin, MD, MPH
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the incidence of non-AIDS–related cancers in HIV-infected individuals in the current HAART era
- Explain efficacy data comparing the use of once- vs twice-daily lopinavir/ritonavir-based therapy in treatment-naive patients
- Discuss the use of atazanavir/ritonavir monotherapy as a simplification strategy in virologically suppressed patients
- Describe the survival benefit of early antiretroviral therapy in HIV-infected infants
- Cite the survival benefit of concomitant HIV/tuberculosis therapy in coinfected patients
Abstract
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|